Eckert Seamans Secures PTAB Victory for Oak Hill Bio Ltd
December 3, 2025
On November 3, 2025, the U.S. Patent Trial and Appeal Board (PTAB) issued a favorable decision for Oak Hill Bio Ltd, reversing prior examiner rejections and strengthening Oak Hill Bio Ltd’s patent position for a pharmaceutical designed to address chronic lung diseases such as Bronchopulmonary Dysplasia (BPD) in premature infants.
Eckert Seamans Member Debora Plehn-Dujowich represented Oak Hill Bio Ltd in the appeal. The patent applicant is Oak Hill Bio Ltd, with Chiesi Farmaceutici S.p.A (“Chiesi”) as the licensee.
The decision followed an oral hearing on October 1, 2025, before a panel of Administrative Patent Judges. This outcome marks a significant step forward in advancing treatments for vulnerable neonatal populations.